Yale Brain Tumor Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 8th floor
New Haven, CT 06511
- Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 8th floorNew Haven, CT 06511
Antonio Omuro, MD
Neuro-Oncology, Neurology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Titles
- Professor of Neurology
- Chief, Neuro-Oncology
- Clinical Trials Director, Chenevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2004)
- MDSao Paulo School of Medicine (1995)
Languages Spoken
- English
- Français (French)
- Português (Portuguese)
- Español (Spanish)
Additional Information
Publications
- Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter. Neuro-oncology 2022 PMID: 35511454, DOI: 10.1093/neuonc/noac116.
- Omuro A. Immune-checkpoint inhibitors for glioblastoma: what have we learned? Arquivos De Neuro-psiquiatria 2022, 80: 266-269. PMID: 35976319, DOI: 10.1590/0004-282X-ANP-2022-S129.
- Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro-oncology 2022 PMID: 35419607, DOI: 10.1093/neuonc/noac099.
- Cassinelli Petersen GI, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, Bahar RC, Merkaj S, Zeevi T, Staib LH, Cui J, Omuro A, Bronen RA, Malhotra A, Aboian MS. Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. AJNR. American Journal Of Neuroradiology 2022, 43: 526-533. PMID: 35361577, PMCID: PMC8993193, DOI: 10.3174/ajnr.A7473.
- Jekel L, Brim WR, von Reppert M, Staib L, Cassinelli Petersen G, Merkaj S, Subramanian H, Zeevi T, Payabvash S, Bousabarah K, Lin M, Cui J, Brackett A, Mahajan A, Omuro A, Johnson MH, Chiang VL, Malhotra A, Scheffler B, Aboian MS. Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review. Cancers 2022, 14 PMID: 35326526, PMCID: PMC8946855, DOI: 10.3390/cancers14061369.
- Joel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/CCI.21.00170.
- Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-oncology Advances 2022, 4: vdac025. PMID: 35402913, PMCID: PMC8989388, DOI: 10.1093/noajnl/vdac025.
- Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-oncology Advances 2022, 4: vdac041. PMID: 35664553, PMCID: PMC9154335, DOI: 10.1093/noajnl/vdac041.
- Cassinelli Petersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Abi Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery. Neuro-oncology Advances 2022, 4: vdac116. PMID: 36043121, PMCID: PMC9412827, DOI: 10.1093/noajnl/vdac116.
- Jansen JA, Omuro A, Lucca LE. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies. Current Opinion In Neurology 2021, 34: 827-833. PMID: 34569985, PMCID: PMC8595795, DOI: 10.1097/WCO.0000000000000988.
- Omuro A. Editorial: Advances in neuro-oncology: stepping in the right direction. Current Opinion In Neurology 2021, 34: 825-826. PMID: 34619693, DOI: 10.1097/WCO.0000000000001000.
- Tavakoli M, Roghaee S, Gunturu M, Omuro AM, Lam BL, Mendoza-Santiesteban CE. Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment. Journal Of Neuro-ophthalmology : The Official Journal Of The North American Neuro-Ophthalmology Society 2021, 41: e324-e325. PMID: 32956221, DOI: 10.1097/WNO.0000000000001076.
- Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.
- A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program.Majersik JJ, Ahmed A, Chen IA, Shill H, Hanes GP, Pelak VS, Hopp JL, Omuro A, Kluger B, Leslie-Mazwi T. A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program. Neurology 2021 PMID: 33931527, DOI: 10.1212/WNL.0000000000012111.
- Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-oncology 2021, 23: 468-477. PMID: 33085768, PMCID: PMC7992893, DOI: 10.1093/neuonc/noaa240.
- Hong CS, Fliney G, Fisayo A, An Y, Gopal PP, Omuro A, Pointdujour-Lim R, Erson-Omay EZ, Omay SB. Genetic characterization of an aggressive optic nerve pilocytic glioma. Brain Tumor Pathology 2021, 38: 59-63. PMID: 33098465, PMCID: PMC7585354, DOI: 10.1007/s10014-020-00383-x.
- Hong CS, Omuro A, An Y, Inzucchi SE, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay EZ. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.
- Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.
- Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncology 2020, 6: 1003-1010. PMID: 32437507, PMCID: PMC7243167, DOI: 10.1001/jamaoncol.2020.1024.
- de la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A. Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine. Neurology® Neuroimmunology & Neuroinflammation 2020, 7 PMID: 32123043, PMCID: PMC7136060, DOI: 10.1212/NXI.0000000000000686.
- Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.
- Aneja S, Omuro A. Imaging biomarkers for brain metastases: more than meets the eye. Neuro-oncology 2019, 21: 1493-1494. PMID: 31777936, PMCID: PMC6917408, DOI: 10.1093/neuonc/noz193.
- Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/WCO.0000000000000756.
- Aneja S, Chang E, Omuro A. Applications of artificial intelligence in neuro-oncology. Current Opinion In Neurology 2019, 32: 850-856. PMID: 31609739, DOI: 10.1097/WCO.0000000000000761.
- Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro AMP, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5537-5547. PMID: 31263031, PMCID: PMC6753053, DOI: 10.1158/1078-0432.CCR-19-0032.
- Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal Of Neuro-oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.
- Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments.Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics 2019, 12: 114. PMID: 31375115, PMCID: PMC6676607, DOI: 10.1186/s12920-019-0563-y.
- Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics 2019, 12: 56. PMID: 31023376, PMCID: PMC6485090, DOI: 10.1186/s12920-019-0500-0.
- de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. American Journal Of Hematology 2019, 94: 455-460. PMID: 30663807, DOI: 10.1002/ajh.25414.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 741-750. PMID: 30715997, PMCID: PMC6553812, DOI: 10.1200/JCO.18.01207.
- Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.CCR-18-2079.
- Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics 2019, 51: 202-206. PMID: 30643254, PMCID: PMC6365097, DOI: 10.1038/s41588-018-0312-8.
- Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood 2018, 132: 2240-2248. PMID: 30262659, PMCID: PMC6265643, DOI: 10.1182/blood-2018-02-835496.
- Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 1702-1709. PMID: 29683790, PMCID: PMC5993168, DOI: 10.1200/JCO.2017.76.9992.
- Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 2018, 287: 667-675. PMID: 29388903, PMCID: PMC5929369, DOI: 10.1148/radiol.2017162610.
- Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research And Opinion 2018, 34: 813-820. PMID: 29025274, DOI: 10.1080/03007995.2017.1392294.
- Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-oncology 2018, 20: 674-686. PMID: 29106665, PMCID: PMC5892140, DOI: 10.1093/neuonc/nox208.
- Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncology 2018, 7: 7-13. PMID: 29388793, PMCID: PMC6001559, DOI: 10.2217/cns-2017-0025.
- Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal Of Radiation Oncology, Biology, Physics 2017, 99: 797-804. PMID: 28870792, PMCID: PMC5654655, DOI: 10.1016/j.ijrobp.2017.06.2466.
- Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-oncology 2017, 19: 1380-1390. PMID: 28472509, PMCID: PMC5596171, DOI: 10.1093/neuonc/nox086.
- Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery 2017, 7: 1018-1029. PMID: 28619981, PMCID: PMC5581705, DOI: 10.1158/2159-8290.CD-17-0613.
- Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.
- Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 1004. PMID: 28777785, DOI: 10.1038/nm0817-1004c.
- Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology 2017, 2017 PMID: 28890946, PMCID: PMC5586540, DOI: 10.1200/PO.17.00011.
- Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 703-713. PMID: 28481359, PMCID: PMC5461196, DOI: 10.1038/nm.4333.
- Hatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.
- Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal Of Neuro-oncology 2017, 132: 181-188. PMID: 28116649, PMCID: PMC5588922, DOI: 10.1007/s11060-016-2357-9.
- Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-oncology 2017, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.
- Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A. "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply. Neuro-oncology 2017, 19: 301-302. PMID: 28040711, PMCID: PMC5464186, DOI: 10.1093/neuonc/now286.
- Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2017, 23: 38-43. PMID: 27713090, PMCID: PMC5518313, DOI: 10.1016/j.bbmt.2016.09.024.
- Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-oncology 2017, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.
- Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 4786-4796. PMID: 27154916, PMCID: PMC5050072, DOI: 10.1158/1078-0432.CCR-16-0048.
- Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-14. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.
- Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia & Lymphoma 2016, 57: 1961-4. PMID: 26727454, DOI: 10.3109/10428194.2015.1120867.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2468-77. PMID: 27269943, PMCID: PMC4962737, DOI: 10.1200/JCO.2015.65.7825.
- Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2404-15. PMID: 27161972, PMCID: PMC4981784, DOI: 10.1200/JCO.2016.66.6487.
- Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-oncology 2016, 18: 873-80. PMID: 26688076, PMCID: PMC4864262, DOI: 10.1093/neuonc/nov301.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology 2016, 18: 557-64. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.
- de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-oncology 2016, 18: 283-90. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.
- Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer 2015, 121: 4165-72. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.
- Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-oncology 2015, 17: 1275-83. PMID: 26019185, PMCID: PMC4588757, DOI: 10.1093/neuonc/nov083.
- Faivre G, Pentsova E, Demopoulos A, Taillibert S, Rosenblum M, Omuro A. Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient. Neurology 2015, 85: e57-61. PMID: 26283762, PMCID: PMC4548283, DOI: 10.1212/WNL.0000000000001848.
- Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-oncology 2015, 17: 440-7. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.
- Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-10. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.
- Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine 2015, 7: 274ra17. PMID: 25673762, PMCID: PMC4431550, DOI: 10.1126/scitranslmed.aaa1009.
- Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leukemia & Lymphoma 2015, 56: 361-7. PMID: 24745937, DOI: 10.3109/10428194.2014.916800.
- Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-oncology 2015, 17: 116-21. PMID: 25100872, PMCID: PMC4483051, DOI: 10.1093/neuonc/nou148.
- Thomas AA, Omuro A. Current role of anti-angiogenic strategies for glioblastoma. Current Treatment Options In Oncology 2014, 15: 551-66. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.
- Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging therapies for glioblastoma. JAMA Neurology 2014, 71: 1437-44. PMID: 25244650, DOI: 10.1001/jamaneurol.2014.1701.
- Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 5023-31. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.CCR-14-0822.
- Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. Neuro-oncology 2014, 16: 1186-95. PMID: 24662514, PMCID: PMC4136896, DOI: 10.1093/neuonc/nou043.
- Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-oncology 2014, 117: 161-5. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.
- Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013, 310: 1842-50. PMID: 24193082, DOI: 10.1001/jama.2013.280319.
- Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, Deangelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology 2013, 81: 1690-6. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.
- Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 3971-9. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/JCO.2013.50.4910.
- Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathology (Zurich, Switzerland) 2013, 23: 584-94. PMID: 23452038, PMCID: PMC8028973, DOI: 10.1111/bpa.12050.
- Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-8. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.
- Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013, 80: 1598-605; discussion 1603. PMID: 23553479, PMCID: PMC3662321, DOI: 10.1212/WNL.0b013e31828f183f.
- Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology 2013, 15: 242-50. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.
- Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & Lymphoma 2013, 54: 58-61. PMID: 22656234, PMCID: PMC4802006, DOI: 10.3109/10428194.2012.698736.
- Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, Shi W, Beal K, Omuro AM. MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging 2013, 37: 41-9. PMID: 23151413, PMCID: PMC4755513, DOI: 10.1016/j.clinimag.2012.02.016.
- Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-oncology 2012, 14: 1304-11. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.
- Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-oncology 2012, 109: 187-93. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.
- Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. Leukemia & Lymphoma 2012, 53: 1620-2. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.
- Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited overall survival in patients with brain metastases from triple negative breast cancer. The Breast Journal 2012, 18: 345-50. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.
- Gupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology 2012, 54: 641-3. PMID: 22006425, PMCID: PMC4724213, DOI: 10.1007/s00234-011-0970-z.
- Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica 2012, 123: 727-38. PMID: 22322993, PMCID: PMC4013829, DOI: 10.1007/s00401-012-0941-4.
- Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D. A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal Of Neuro-oncology 2012, 107: 343-9. PMID: 22048878, DOI: 10.1007/s11060-011-0747-6.
- Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: 382-5. PMID: 22089116, DOI: 10.1097/JTO.0b013e3182398e4f.
- Omuro AM, Martin-Duverneuil N, Delattre JY. Complications of radiotherapy to the central nervous system. Handbook Of Clinical Neurology 2012, 105: 887-901. PMID: 22230540, DOI: 10.1016/B978-0-444-53502-3.00030-6.
- Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 2012, 14: 101-8. PMID: 22013168, PMCID: PMC3245999, DOI: 10.1093/neuonc/nor186.
- Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-oncology 2012, 106: 143-6. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.
- Graber JJ, Omuro A. Primary central nervous system lymphoma: is there still a role for radiotherapy? Current Opinion In Neurology 2011, 24: 633-40. PMID: 21968551, DOI: 10.1097/WCO.0b013e32834cbdef.
- Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-7. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.
- Omuro A, Taillandier L, Chinot O, Sierra Del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Journal Of Neuro-oncology 2011, 104: 323-30. PMID: 21170569, DOI: 10.1007/s11060-010-0497-x.
- Graber JJ, Omuro A. Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate? CNS Drugs 2011, 25: 447-57. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.
- Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Journal Of Neuro-oncology 2011, 101: 457-62. PMID: 20556480, DOI: 10.1007/s11060-010-0264-z.
- De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal Of Neuro-oncology 2010, 100: 443-7. PMID: 20440540, PMCID: PMC3246379, DOI: 10.1007/s11060-010-0200-2.
- Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. Journal Of Neuro-oncology 2010, 100: 439-41. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.
- Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Current Opinion In Investigational Drugs (London, England : 2000) 2008, 9: 1287-95. PMID: 19037835.
- Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-9. PMID: 18989118, DOI: 10.1097/WCO.0b013e3283184625.
- Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal Of Cancer (Oxford, England : 1990) 2008, 44: 1210-6. PMID: 18248979, DOI: 10.1016/j.ejca.2007.12.005.
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 2512-8. PMID: 18413641, DOI: 10.1200/JCO.2007.13.5533.
- Omuro AM. What is the relevance of determining EGFR-variant-III status in glioblastomas? Nature Clinical Practice. Oncology 2008, 5: 188-9. PMID: 18319741, DOI: 10.1038/ncponc1074.
- Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. Journal Of Neuro-oncology 2008, 87: 85-90. PMID: 17987262, DOI: 10.1007/s11060-007-9491-3.
- Omuro AM, Delattre JY. Brain tumors and dementia. Handbook Of Clinical Neurology 2008, 89: 877-86. PMID: 18631803, DOI: 10.1016/S0072-9752(07)01277-8.
- Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-7. PMID: 17992093, DOI: 10.1097/WCO.0b013e3282f1beef.
- Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-11. PMID: 17906460, DOI: 10.1097/CCO.0b013e3282f075f3.
- Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-oncology 2007, 85: 207-11. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.
- Omuro AM. Is single-agent temozolomide the treatment of choice for recurrent primary central nervous system lymphoma? Nature Clinical Practice. Oncology 2007, 4: 514-5. PMID: 17622233, DOI: 10.1038/ncponc0898.
- Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Molecular Cancer Therapeutics 2007, 6: 1909-19. PMID: 17620423, DOI: 10.1158/1535-7163.MCT-07-0047.
- Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Dynamic history of low-grade gliomas before and after temozolomide treatment. Annals Of Neurology 2007, 61: 484-90. PMID: 17469128, DOI: 10.1002/ana.21125.
- Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical Focus 2006, 21: E12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.
- Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. The Lancet. Neurology 2006, 5: 937-48. PMID: 17052661, DOI: 10.1016/S1474-4422(06)70597-X.
- Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. Journal Of Neuro-oncology 2006, 78: 277-80. PMID: 16614943, DOI: 10.1007/s11060-005-9095-8.
- Mutarelli EG, Omuro AM, Adoni T. Hypersexuality following bilateral thalamic infarction: case report. Arquivos De Neuro-psiquiatria 2006, 64: 146-8. PMID: 16622574, DOI: 10.1590/s0004-282x2006000100032.
- Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005, 104: 2473-6. PMID: 16270316, DOI: 10.1002/cncr.21564.
- Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE. Delayed neurotoxicity in primary central nervous system lymphoma. Archives Of Neurology 2005, 62: 1595-600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.
- Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103: 2344-8. PMID: 15844174, DOI: 10.1002/cncr.21033.
- Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005, 64: 1625-7. PMID: 15883329, DOI: 10.1212/01.WNL.0000160396.69050.DC.
- Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.WNL.0000148641.98241.5E.
- Omuro AM, Abrey LE. Brain metastases. Current Neurology And Neuroscience Reports 2004, 4: 205-10. PMID: 15102346, DOI: 10.1007/s11910-004-0040-6.
Departments and Programs
Locations
Yale Brain Tumor Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 8th floor
New Haven, CT 06511
- Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 8th floorNew Haven, CT 06511
Titles
- Professor of Neurology
- Chief, Neuro-Oncology
- Clinical Trials Director, Chenevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2004)
- MDSao Paulo School of Medicine (1995)
Languages Spoken
- English
- Français (French)
- Português (Portuguese)
- Español (Spanish)
Additional Information
Publications
- Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter. Neuro-oncology 2022 PMID: 35511454, DOI: 10.1093/neuonc/noac116.
- Omuro A. Immune-checkpoint inhibitors for glioblastoma: what have we learned? Arquivos De Neuro-psiquiatria 2022, 80: 266-269. PMID: 35976319, DOI: 10.1590/0004-282X-ANP-2022-S129.
- Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro-oncology 2022 PMID: 35419607, DOI: 10.1093/neuonc/noac099.
- Cassinelli Petersen GI, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, Bahar RC, Merkaj S, Zeevi T, Staib LH, Cui J, Omuro A, Bronen RA, Malhotra A, Aboian MS. Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. AJNR. American Journal Of Neuroradiology 2022, 43: 526-533. PMID: 35361577, PMCID: PMC8993193, DOI: 10.3174/ajnr.A7473.
- Jekel L, Brim WR, von Reppert M, Staib L, Cassinelli Petersen G, Merkaj S, Subramanian H, Zeevi T, Payabvash S, Bousabarah K, Lin M, Cui J, Brackett A, Mahajan A, Omuro A, Johnson MH, Chiang VL, Malhotra A, Scheffler B, Aboian MS. Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review. Cancers 2022, 14 PMID: 35326526, PMCID: PMC8946855, DOI: 10.3390/cancers14061369.
- Joel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/CCI.21.00170.
- Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-oncology Advances 2022, 4: vdac025. PMID: 35402913, PMCID: PMC8989388, DOI: 10.1093/noajnl/vdac025.
- Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-oncology Advances 2022, 4: vdac041. PMID: 35664553, PMCID: PMC9154335, DOI: 10.1093/noajnl/vdac041.
- Cassinelli Petersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Abi Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery. Neuro-oncology Advances 2022, 4: vdac116. PMID: 36043121, PMCID: PMC9412827, DOI: 10.1093/noajnl/vdac116.
- Jansen JA, Omuro A, Lucca LE. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies. Current Opinion In Neurology 2021, 34: 827-833. PMID: 34569985, PMCID: PMC8595795, DOI: 10.1097/WCO.0000000000000988.
- Omuro A. Editorial: Advances in neuro-oncology: stepping in the right direction. Current Opinion In Neurology 2021, 34: 825-826. PMID: 34619693, DOI: 10.1097/WCO.0000000000001000.
- Tavakoli M, Roghaee S, Gunturu M, Omuro AM, Lam BL, Mendoza-Santiesteban CE. Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment. Journal Of Neuro-ophthalmology : The Official Journal Of The North American Neuro-Ophthalmology Society 2021, 41: e324-e325. PMID: 32956221, DOI: 10.1097/WNO.0000000000001076.
- Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.
- A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program.Majersik JJ, Ahmed A, Chen IA, Shill H, Hanes GP, Pelak VS, Hopp JL, Omuro A, Kluger B, Leslie-Mazwi T. A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program. Neurology 2021 PMID: 33931527, DOI: 10.1212/WNL.0000000000012111.
- Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-oncology 2021, 23: 468-477. PMID: 33085768, PMCID: PMC7992893, DOI: 10.1093/neuonc/noaa240.
- Hong CS, Fliney G, Fisayo A, An Y, Gopal PP, Omuro A, Pointdujour-Lim R, Erson-Omay EZ, Omay SB. Genetic characterization of an aggressive optic nerve pilocytic glioma. Brain Tumor Pathology 2021, 38: 59-63. PMID: 33098465, PMCID: PMC7585354, DOI: 10.1007/s10014-020-00383-x.
- Hong CS, Omuro A, An Y, Inzucchi SE, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay EZ. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.
- Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.
- Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncology 2020, 6: 1003-1010. PMID: 32437507, PMCID: PMC7243167, DOI: 10.1001/jamaoncol.2020.1024.
- de la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A. Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine. Neurology® Neuroimmunology & Neuroinflammation 2020, 7 PMID: 32123043, PMCID: PMC7136060, DOI: 10.1212/NXI.0000000000000686.
- Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.
- Aneja S, Omuro A. Imaging biomarkers for brain metastases: more than meets the eye. Neuro-oncology 2019, 21: 1493-1494. PMID: 31777936, PMCID: PMC6917408, DOI: 10.1093/neuonc/noz193.
- Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/WCO.0000000000000756.
- Aneja S, Chang E, Omuro A. Applications of artificial intelligence in neuro-oncology. Current Opinion In Neurology 2019, 32: 850-856. PMID: 31609739, DOI: 10.1097/WCO.0000000000000761.
- Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro AMP, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5537-5547. PMID: 31263031, PMCID: PMC6753053, DOI: 10.1158/1078-0432.CCR-19-0032.
- Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal Of Neuro-oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.
- Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments.Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics 2019, 12: 114. PMID: 31375115, PMCID: PMC6676607, DOI: 10.1186/s12920-019-0563-y.
- Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics 2019, 12: 56. PMID: 31023376, PMCID: PMC6485090, DOI: 10.1186/s12920-019-0500-0.
- de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. American Journal Of Hematology 2019, 94: 455-460. PMID: 30663807, DOI: 10.1002/ajh.25414.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 741-750. PMID: 30715997, PMCID: PMC6553812, DOI: 10.1200/JCO.18.01207.
- Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.CCR-18-2079.
- Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics 2019, 51: 202-206. PMID: 30643254, PMCID: PMC6365097, DOI: 10.1038/s41588-018-0312-8.
- Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood 2018, 132: 2240-2248. PMID: 30262659, PMCID: PMC6265643, DOI: 10.1182/blood-2018-02-835496.
- Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 1702-1709. PMID: 29683790, PMCID: PMC5993168, DOI: 10.1200/JCO.2017.76.9992.
- Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 2018, 287: 667-675. PMID: 29388903, PMCID: PMC5929369, DOI: 10.1148/radiol.2017162610.
- Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research And Opinion 2018, 34: 813-820. PMID: 29025274, DOI: 10.1080/03007995.2017.1392294.
- Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-oncology 2018, 20: 674-686. PMID: 29106665, PMCID: PMC5892140, DOI: 10.1093/neuonc/nox208.
- Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncology 2018, 7: 7-13. PMID: 29388793, PMCID: PMC6001559, DOI: 10.2217/cns-2017-0025.
- Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal Of Radiation Oncology, Biology, Physics 2017, 99: 797-804. PMID: 28870792, PMCID: PMC5654655, DOI: 10.1016/j.ijrobp.2017.06.2466.
- Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-oncology 2017, 19: 1380-1390. PMID: 28472509, PMCID: PMC5596171, DOI: 10.1093/neuonc/nox086.
- Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery 2017, 7: 1018-1029. PMID: 28619981, PMCID: PMC5581705, DOI: 10.1158/2159-8290.CD-17-0613.
- Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.
- Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 1004. PMID: 28777785, DOI: 10.1038/nm0817-1004c.
- Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology 2017, 2017 PMID: 28890946, PMCID: PMC5586540, DOI: 10.1200/PO.17.00011.
- Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 703-713. PMID: 28481359, PMCID: PMC5461196, DOI: 10.1038/nm.4333.
- Hatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.
- Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal Of Neuro-oncology 2017, 132: 181-188. PMID: 28116649, PMCID: PMC5588922, DOI: 10.1007/s11060-016-2357-9.
- Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-oncology 2017, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.
- Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A. "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply. Neuro-oncology 2017, 19: 301-302. PMID: 28040711, PMCID: PMC5464186, DOI: 10.1093/neuonc/now286.
- Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2017, 23: 38-43. PMID: 27713090, PMCID: PMC5518313, DOI: 10.1016/j.bbmt.2016.09.024.
- Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-oncology 2017, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.
- Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 4786-4796. PMID: 27154916, PMCID: PMC5050072, DOI: 10.1158/1078-0432.CCR-16-0048.
- Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-14. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.
- Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia & Lymphoma 2016, 57: 1961-4. PMID: 26727454, DOI: 10.3109/10428194.2015.1120867.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2468-77. PMID: 27269943, PMCID: PMC4962737, DOI: 10.1200/JCO.2015.65.7825.
- Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2404-15. PMID: 27161972, PMCID: PMC4981784, DOI: 10.1200/JCO.2016.66.6487.
- Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-oncology 2016, 18: 873-80. PMID: 26688076, PMCID: PMC4864262, DOI: 10.1093/neuonc/nov301.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology 2016, 18: 557-64. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.
- de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-oncology 2016, 18: 283-90. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.
- Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer 2015, 121: 4165-72. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.
- Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-oncology 2015, 17: 1275-83. PMID: 26019185, PMCID: PMC4588757, DOI: 10.1093/neuonc/nov083.
- Faivre G, Pentsova E, Demopoulos A, Taillibert S, Rosenblum M, Omuro A. Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient. Neurology 2015, 85: e57-61. PMID: 26283762, PMCID: PMC4548283, DOI: 10.1212/WNL.0000000000001848.
- Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-oncology 2015, 17: 440-7. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.
- Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-10. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.
- Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine 2015, 7: 274ra17. PMID: 25673762, PMCID: PMC4431550, DOI: 10.1126/scitranslmed.aaa1009.
- Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leukemia & Lymphoma 2015, 56: 361-7. PMID: 24745937, DOI: 10.3109/10428194.2014.916800.
- Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-oncology 2015, 17: 116-21. PMID: 25100872, PMCID: PMC4483051, DOI: 10.1093/neuonc/nou148.
- Thomas AA, Omuro A. Current role of anti-angiogenic strategies for glioblastoma. Current Treatment Options In Oncology 2014, 15: 551-66. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.
- Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging therapies for glioblastoma. JAMA Neurology 2014, 71: 1437-44. PMID: 25244650, DOI: 10.1001/jamaneurol.2014.1701.
- Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 5023-31. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.CCR-14-0822.
- Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. Neuro-oncology 2014, 16: 1186-95. PMID: 24662514, PMCID: PMC4136896, DOI: 10.1093/neuonc/nou043.
- Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-oncology 2014, 117: 161-5. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.
- Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013, 310: 1842-50. PMID: 24193082, DOI: 10.1001/jama.2013.280319.
- Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, Deangelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology 2013, 81: 1690-6. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.
- Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2013, 31: 3971-9. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/JCO.2013.50.4910.
- Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathology (Zurich, Switzerland) 2013, 23: 584-94. PMID: 23452038, PMCID: PMC8028973, DOI: 10.1111/bpa.12050.
- Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-8. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.
- Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013, 80: 1598-605; discussion 1603. PMID: 23553479, PMCID: PMC3662321, DOI: 10.1212/WNL.0b013e31828f183f.
- Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology 2013, 15: 242-50. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.
- Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & Lymphoma 2013, 54: 58-61. PMID: 22656234, PMCID: PMC4802006, DOI: 10.3109/10428194.2012.698736.
- Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, Shi W, Beal K, Omuro AM. MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging 2013, 37: 41-9. PMID: 23151413, PMCID: PMC4755513, DOI: 10.1016/j.clinimag.2012.02.016.
- Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-oncology 2012, 14: 1304-11. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.
- Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-oncology 2012, 109: 187-93. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.
- Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. Leukemia & Lymphoma 2012, 53: 1620-2. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.
- Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited overall survival in patients with brain metastases from triple negative breast cancer. The Breast Journal 2012, 18: 345-50. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.
- Gupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology 2012, 54: 641-3. PMID: 22006425, PMCID: PMC4724213, DOI: 10.1007/s00234-011-0970-z.
- Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica 2012, 123: 727-38. PMID: 22322993, PMCID: PMC4013829, DOI: 10.1007/s00401-012-0941-4.
- Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D. A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal Of Neuro-oncology 2012, 107: 343-9. PMID: 22048878, DOI: 10.1007/s11060-011-0747-6.
- Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: 382-5. PMID: 22089116, DOI: 10.1097/JTO.0b013e3182398e4f.
- Omuro AM, Martin-Duverneuil N, Delattre JY. Complications of radiotherapy to the central nervous system. Handbook Of Clinical Neurology 2012, 105: 887-901. PMID: 22230540, DOI: 10.1016/B978-0-444-53502-3.00030-6.
- Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 2012, 14: 101-8. PMID: 22013168, PMCID: PMC3245999, DOI: 10.1093/neuonc/nor186.
- Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-oncology 2012, 106: 143-6. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.
- Graber JJ, Omuro A. Primary central nervous system lymphoma: is there still a role for radiotherapy? Current Opinion In Neurology 2011, 24: 633-40. PMID: 21968551, DOI: 10.1097/WCO.0b013e32834cbdef.
- Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-7. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.
- Omuro A, Taillandier L, Chinot O, Sierra Del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Journal Of Neuro-oncology 2011, 104: 323-30. PMID: 21170569, DOI: 10.1007/s11060-010-0497-x.
- Graber JJ, Omuro A. Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate? CNS Drugs 2011, 25: 447-57. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.
- Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Journal Of Neuro-oncology 2011, 101: 457-62. PMID: 20556480, DOI: 10.1007/s11060-010-0264-z.
- De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal Of Neuro-oncology 2010, 100: 443-7. PMID: 20440540, PMCID: PMC3246379, DOI: 10.1007/s11060-010-0200-2.
- Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. Journal Of Neuro-oncology 2010, 100: 439-41. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.
- Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Current Opinion In Investigational Drugs (London, England : 2000) 2008, 9: 1287-95. PMID: 19037835.
- Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-9. PMID: 18989118, DOI: 10.1097/WCO.0b013e3283184625.
- Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal Of Cancer (Oxford, England : 1990) 2008, 44: 1210-6. PMID: 18248979, DOI: 10.1016/j.ejca.2007.12.005.
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 2512-8. PMID: 18413641, DOI: 10.1200/JCO.2007.13.5533.
- Omuro AM. What is the relevance of determining EGFR-variant-III status in glioblastomas? Nature Clinical Practice. Oncology 2008, 5: 188-9. PMID: 18319741, DOI: 10.1038/ncponc1074.
- Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. Journal Of Neuro-oncology 2008, 87: 85-90. PMID: 17987262, DOI: 10.1007/s11060-007-9491-3.
- Omuro AM, Delattre JY. Brain tumors and dementia. Handbook Of Clinical Neurology 2008, 89: 877-86. PMID: 18631803, DOI: 10.1016/S0072-9752(07)01277-8.
- Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-7. PMID: 17992093, DOI: 10.1097/WCO.0b013e3282f1beef.
- Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-11. PMID: 17906460, DOI: 10.1097/CCO.0b013e3282f075f3.
- Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-oncology 2007, 85: 207-11. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.
- Omuro AM. Is single-agent temozolomide the treatment of choice for recurrent primary central nervous system lymphoma? Nature Clinical Practice. Oncology 2007, 4: 514-5. PMID: 17622233, DOI: 10.1038/ncponc0898.
- Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Molecular Cancer Therapeutics 2007, 6: 1909-19. PMID: 17620423, DOI: 10.1158/1535-7163.MCT-07-0047.
- Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Dynamic history of low-grade gliomas before and after temozolomide treatment. Annals Of Neurology 2007, 61: 484-90. PMID: 17469128, DOI: 10.1002/ana.21125.
- Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical Focus 2006, 21: E12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.
- Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. The Lancet. Neurology 2006, 5: 937-48. PMID: 17052661, DOI: 10.1016/S1474-4422(06)70597-X.
- Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. Journal Of Neuro-oncology 2006, 78: 277-80. PMID: 16614943, DOI: 10.1007/s11060-005-9095-8.
- Mutarelli EG, Omuro AM, Adoni T. Hypersexuality following bilateral thalamic infarction: case report. Arquivos De Neuro-psiquiatria 2006, 64: 146-8. PMID: 16622574, DOI: 10.1590/s0004-282x2006000100032.
- Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005, 104: 2473-6. PMID: 16270316, DOI: 10.1002/cncr.21564.
- Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE. Delayed neurotoxicity in primary central nervous system lymphoma. Archives Of Neurology 2005, 62: 1595-600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.
- Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103: 2344-8. PMID: 15844174, DOI: 10.1002/cncr.21033.
- Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005, 64: 1625-7. PMID: 15883329, DOI: 10.1212/01.WNL.0000160396.69050.DC.
- Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.WNL.0000148641.98241.5E.
- Omuro AM, Abrey LE. Brain metastases. Current Neurology And Neuroscience Reports 2004, 4: 205-10. PMID: 15102346, DOI: 10.1007/s11910-004-0040-6.
Departments and Programs
Locations
Yale Brain Tumor Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 8th floor
New Haven, CT 06511
- Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 8th floorNew Haven, CT 06511
Yale Brain Tumor Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 8th floor
New Haven, CT 06511
- Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 8th floorNew Haven, CT 06511